MedCityNews is the leading online news source for the business of innovation in healthcare.
“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”
Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC
Takeda announced positive late-stage results for its new type 2 diabetes drug, fasiglifam (TAK-875), the first GPR40 agonist to reach late-stage development. Fasiglifam has the potential to be a compelling…